Investing now, at scale and as a collective global effort is vital to change the course of the pandemic.
At least $8 billion of new funding is needed for the global response to COVID-19 – for research, development and supply of treatments for all, and support for public health measures in countries with the weakest health systems.
COVID-Zero is a global coalition of partners, organised by Wellcome, to advocate for closing the initial $8 billion funding gap. Find out how your business can join.
Research is the best way to save lives, bring the COVID-19 pandemic to an end and prevent it reappearing. Across the world, researchers are racing to develop and test vaccines, tests and treatments.
We’re supporting global research efforts through CEPI, the Coalition for Epidemic Preparedness Innovations, the COVID-19 Therapeutics Accelerator, and our COVID-19 funding call.
We're also calling on researchers, journals and funders to share their research data and findings rapidly and openly.
All R&D funders, developers, manufacturers and governments must help to make sure that new vaccines, tests and treatments developed for COVID-19 are globally available, appropriate and affordable for everyone, regardless of where they have been developed or who has funded them.
During the COVID-19 pandemic, researchers and publishers have pulled together to publish their outputs at an unprecedented rate. How will this change research culture and the way findings are disseminated in future?
On 4 May, world leaders and health organisations pledged billions for the COVID-19 response. Alex Harris explains that urgent funding gaps remain for research.
A COVID-19 vaccine would be an incredibly powerful tool to slow down the coronavirus pandemic. How do we develop one in record time?
Our polling of more than 6,000 adults in the UK, the USA, Germany and France shows strong public support for making sure that any new coronavirus treatments and vaccines are first made available to those who need them most.